Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Glynn Wilson and Keith Knutson have both lost family members to breast cancer. Glynn lost his wife. They are both motivated to cure breast cancer and will find a way to overcome the short selling of TPIV stock to get their technologies through the FDA process. The strong survive.
I do too! When do you think we get some news?
Research Keith Knutson and what he is trying to accomplish with curing breast and ovarian cancer. Google him on YouTube to listen to some of his presentations.
Maybe the SEC and FINRA should monitor his trading activities? Novel idea!
Oh ok, then it is the shorters who are indirectly killing God's unfortunate people who are stricken with breast and ovarian cancer! Shorters of any biotech stock must be soulless and heartless money grubbing ghouls!
Sellers of TPIV stock are literally killing breast and ovarian cancer patients by ruining this company and delaying them in getting trials completed. Congratulations on your good work!
I plan to build a small position in Genethera and then hold it for a very long time. No trading of GTHR shares for me. I have learned with promising biotechs that you can never estimate how big they will eventually become.
The new investor relations contact appearing at the end of press releases must have some good contacts to get all these good stories about TapImmune out there. I am not worried about patents because we are filing patents for PolyStart and Mayo has the new antigens covered. No problem there.
I see 32 million outstanding shares
There has been more volume recently versus trading in the spring and summer. I also see TPIV has an outsourced Investor Relations contact in NY. Maybe they can help with awareness building among institutions but we need to get off the Bulletin Board. That has been a goal of Glynn Wilson's for some time.
TPIV should be a $500 million market cap company when we officially launch Phase 2 trials. I am convinced some disgruntled or plain evil people are manipulating our stock price. In time they will be found out and prosecuted!
How many shares outstanding does GTHR have?
TapImmune will be a great company but TPIV stock sucks now because it is probably manipulated on the bulletin board. Press releases have been promising we are uplisting to NASDAQ at some point. Can't happen fast enough for me.
Remember Koos has significant personal funds invested in BMSN and ENTB. They will
all go up big at some point. He knows what's going on and has invested his own money. What does that tell you?
TPIV should be at $4 minimum based on this excellent news! Can't wait until we get away from the evil
traders on the disgusting bulletin board exchange. Someone is ruining our value!
Looks like no NASDAQ this year. Can't hold a dollar. What a huge disappointment. The news flow stopped and the stock price sank. No mystery there. Need a constant news flow. Wish they had waited to do the reverse split until they could guarantee a steady news stream.
But ENTB focuses on cancer stem cells and Christine Ichim, brother of Tom our CSO at Regen, is leading the cell senescence approach there first for feline leukemia and canine cancer. I want one that focuses solely on leading the RNAi field.
Wish Koos would create another subsidiary focusing on RNAi.
We may cross $2 by the end of the week.
Since Galena had a successful Phase 2 result which prompted a Phase 3 test, I have to believe that with better epitopes, TapImmune will also have a successful Phase 2 that will lead to Phase 3.
Also, Merck's success with Keytruda will definitely put immunotherapy into the spotlight which only helps TapImmune find more investors. Didn't they talk about immunotherapy during that Cancer broadcast special on tv last night? I didn't see it but someone mentioned that.
My confidence in TapImmune's approach lies in the fact that Knutson's new her2 neu epitopes licensed to TapImmune in April 2012 are naturally processed in the proteasome as opposed to the Galena epitope which is not naturally processed. I am not a scientist but this is what I have learned through extensive research watching all the YouTube videos of Knutson and Glynn Wilson and reading all the info I could find.
PolyStart will help us target all the new antigens Knutson and his team will probably discover over the next several years. PolyStart will be a huge revenue generator in the future. Just have to wait patiently until our Phase 2 data blows away anything released by Galena.
Thank you! They must expect news soon to support the share price. Why else would they go live now?
Am I the only one who can't see this trading anywhere? What am I missing?
Seriously, is Regen stock trading today? What exchange is it on?
Regen Biopharma and Entest have the potential to become multi billion dollar market cap companies within 5-7 years. David Koos is working with very innovative folks and will succeed in time. Patience will pay huge rewards in the future.
Google "Ichim family matriarch dies" and read about why Christine Ichim and her brother Tom are exceptional people and why they are probably highly motivated to cure leukemia.
Google "Ichim family matriarch dies" and read about why Christine Ichim and her brother Tom are exceptional people who probably have a great motivation to cure leukemia.
TPIV stock price over the next year is meaningless. I am holding until at least the end of 2016 or into 2017. The full value will not be realized until then. Lots of waiting to get through. These trials take longer than people think. Patience is a virtue with biotech.
TPIV will revolutionize care for ovarian and breast cancer eventually despite the actions of manipulators and vultures. Get us off the OCTBB!
Marina will be a $2 billion market cap company sooner than we think!
Look at MRNA stock today when they regained SEC compliance! We need the same yesterday! Glynn Wilson seems to be working toward that goal.
Google "Scientist prepares to test vaccine to fight breast, ovarian cancers" dated Oct 2, 2011. In it you will read about Keith Knutson and how he has family members with breast cancer. He is clearly motivated to cure breast cancer. I will bet on him and his research combined with TapImmune's technology.
What other biotechs are you in?
I feel bad for Glynn Wilson. Evil people and vultures have been trying to destroy TapImmune. Hope none of their family ever waits desperately for a cancer cure only to die waiting as my family has experienced.
I was fooled again. Fell in love with the science and did not pay attention to the dire financial
situation. Afraid it will be months before I get back to even. Should have sold everything at $5. I'll never learn.
These vultures that ruin our value should be required to talk face to face with cancer patients and tell them "
I would rather see you die than pay a fair price for a compamy's stock that could save your life!"
Seems like the institution that invested waited until we had a lull in news and the stock price was worked down near a dollar. Smart. But it slows us down and patients die every day while vultures play these games. Disgusting.
Glad they only sold $2 million in stock to one institution. Probably enough to finish Phase 1 for all trials and then once they advance to Phase 2 they can do another stock offering at much higher prices.
I hope it's not at $1. That would be terrible. I never sold a share over the last 4 months! How stupid was that! You were smarter Salix. Now you can buy back at ridiculous prices.